ES527027A0 - Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas - Google Patents

Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas

Info

Publication number
ES527027A0
ES527027A0 ES527027A ES527027A ES527027A0 ES 527027 A0 ES527027 A0 ES 527027A0 ES 527027 A ES527027 A ES 527027A ES 527027 A ES527027 A ES 527027A ES 527027 A0 ES527027 A0 ES 527027A0
Authority
ES
Spain
Prior art keywords
imidazolylalkylliten
tetrahydropyridazines
preparing
procedure
imidazolylalkylthienyltetrahydropyridazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES527027A
Other languages
English (en)
Other versions
ES8406472A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of ES8406472A1 publication Critical patent/ES8406472A1/es
Publication of ES527027A0 publication Critical patent/ES527027A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
ES527027A 1982-11-06 1983-11-04 Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas Granted ES527027A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823241102 DE3241102A1 (de) 1982-11-06 1982-11-06 Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
ES8406472A1 ES8406472A1 (es) 1984-07-01
ES527027A0 true ES527027A0 (es) 1984-07-01

Family

ID=6177509

Family Applications (1)

Application Number Title Priority Date Filing Date
ES527027A Granted ES527027A0 (es) 1982-11-06 1983-11-04 Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas

Country Status (11)

Country Link
US (1) US4643998A (es)
EP (1) EP0112987B1 (es)
JP (1) JPS59108781A (es)
AT (1) ATE26274T1 (es)
DE (2) DE3241102A1 (es)
DK (1) DK156660C (es)
ES (1) ES527027A0 (es)
GR (1) GR78945B (es)
IE (1) IE56127B1 (es)
PT (1) PT77616B (es)
ZA (1) ZA837976B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407509A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Neue arzneimittelkombination zur behandlung von bluthochdruck und thromboembolischen erkrankungen
DE3606105A1 (de) * 1986-02-26 1987-08-27 Nattermann A & Cie Verfahren zur herstellung von imidazolyl-thiophenaldehyden
DE3626865A1 (de) * 1986-08-08 1988-02-11 Boehringer Mannheim Gmbh Neue pyridazinon-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004036075B3 (de) * 2004-07-24 2006-02-16 Bos Gmbh & Co. Kg Anordnung für Seitenfensterrollo
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
MX2016001714A (es) 2013-08-09 2016-10-03 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
EP3287453A4 (en) * 2015-04-24 2018-02-28 Medshine Discovery Inc. Imidazole compound
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
WO2018072702A1 (zh) * 2016-10-20 2018-04-26 南京明德新药研发股份有限公司 一种咪唑类化合物的晶型、盐型及其制备方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130252A1 (de) * 1981-07-31 1983-02-17 A. Nattermann & Cie GmbH, 5000 Köln 6-(5-((omega)-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydro-pyridazine und deren saeureadditionssalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
HU190412B (en) * 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) * 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones

Also Published As

Publication number Publication date
ES8406472A1 (es) 1984-07-01
DK156660B (da) 1989-09-18
DK156660C (da) 1990-03-05
JPH054391B2 (es) 1993-01-19
PT77616B (en) 1986-03-19
ATE26274T1 (de) 1987-04-15
DK505983A (da) 1984-05-07
IE832484L (en) 1984-05-06
DE3370626D1 (en) 1987-05-07
JPS59108781A (ja) 1984-06-23
GR78945B (es) 1984-10-02
ZA837976B (en) 1984-06-27
US4643998A (en) 1987-02-17
PT77616A (en) 1983-12-01
EP0112987B1 (de) 1987-04-01
EP0112987A1 (de) 1984-07-11
DE3241102A1 (de) 1984-05-10
IE56127B1 (en) 1991-04-24
DK505983D0 (da) 1983-11-04

Similar Documents

Publication Publication Date Title
ES527027A0 (es) Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas
ES524512A0 (es) Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos
ES491224A0 (es) Procedimiento para la preparacion de anilidas de acidos 4- amino-2-ureido-(o-tioureido)-pirimidin-5-carboxilicos
FI793238A (fi) Difenylbutyl-piperazinekarboxamider
NO820686L (no) Fremgangsmaate ved fremstilling av nye aroylimidazoloner
ES485489A0 (es) Procedimiento para la preparacion de derivados de pirimido-(6,1-a)-isoquinolein-4-onas
ES521086A0 (es) Procedimiento para la preparacion de imidazolilfenil-tetrahidropiridazinas.
SE8700506D0 (sv) Fenoxialkansyraestrar
ES557516A0 (es) Procedimiento para la obtencion del acido 2,6-dicloro-5-fluor-piridin-3-carboxilico
ES554305A0 (es) Procedimiento para la fabricacion de derivados quinolilglicinamidas
ES554634A0 (es) Procedimiento para preparar 2(1h)-piridonas
ES490069A0 (es) Procedimiento para la preparacion de derivados de amidas de acidos 1,2,3-tiadiazol-5-carboxilicos
IL65936A (en) Chloroacetic acid cyclohexylamides,their preparation and their use as herbicides
ES530073A0 (es) Procedimiento para preparar la n-(3-trifluorometil fenil)-n-propargil-piperazina.
MX6164E (es) Procedimiento microbiologico mejorado para la preparacion del acido 2,5-dicetogluconico
ES494417A0 (es) Procedimiento para la preparacion de 2-(2-cloro-4-ciclopro- pil-fenil-imino)-imidazolidina
IT8009431A0 (it) Procedimento di sterilizzazione impiegante un coadiuvante dell'azione del calore

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960506